This meeting was 16 days ago! Who knows when the publication comes out, but this is confirmation of what it will contain. Surly needs some RNS of interim finding now these sage minutes have been published
18. A Human Challenge Study has taken place in which young health volunteers were administered a controlled low dose of SARS-CoV2. An acceptable infection rate was achieved, symptoms were mild, and the study was safely completed. The study will reveal kinetics of viral shedding particularly early after infection and allow assessments of lateral flow tests. Environmental and air samples were used to monitor emissions to the environment.
We have provided a high-level overview of the discussion on the Human Challenge Studies which is awaiting publication in a journal. The full details of the discussion will be available once the paper is published
I believe the tech was already under development with Peptcell before the partnership with hVivo as they were working on a HIV vaccine. Whether they put this underlying vaccine development IP into the Imutex vehicle to match hVivo's cash and study hosting I don't know. So it's hard to know if we will benefit from future developments.
Assuming we get shares in ConserV Biosciences when it floats, we will benefit from the developments. If we get cash we gain nothing from it.
It's just something fun someone else made, you guys all take this to seriously. I've got all my holdings in Orph and despite the 33% drop, and CFs wildly unrealistic promises, CF would have to be truly incompetent not to make a huge success from open orphan assets and make us all a lot of money in the process. I've held for years and intend to hold until I'm bought out by SGS
Years ago when developing their asthma challenge trials methodology, they were also doing Pathomics analysis of the biological data to discover new targets in the disease to target. Now asthma is a big market. If a nonsteroidal treatment could be developed from their work Poolbeg would be a monster company, would probably quickly be bought out
They used Pathomics to find the biological target for severe flu treatment, then looked for a molecule that could target it and found the compound that became HVO-001.
This methodology of looking in immensely fine details at the biochemical pathways to find a point that you could intervene then finding a molecule that would change the pathway is what I think is the biggest value IP in Poolbeg.
Earache, have a look through old hVivo RNS about Pathomics and you'll discover where a lot of the extra Poolbeg IP is coming from. I've posted about this previously. They have some genuinely innovative approaches that were only half developed under old management
Cathal's slice of the Poolbeg pie14 Jun 2021 22:57
If we take shares in issue from recent exercise of warrants RNS, divide by 2.98 to work out new Poolbeg shares, and add existing poolbeg shares you get 250,116,628 shares. If my maths is correct the existing 5 Poolbeg holders are getting just shy of 10% (24,997,500 shares), with CF getting 6%. That roughly doubles his share of the spin off compared to his open Orphan holding. He's done very well for himself there
RE: New companies House documents08 Jun 2021 08:42
The previous shares in issue was 24997500, the confirmation statement on 24th May gives this value. It was just one share owned by Open Orphan originally, then 24997500 divided among the 5 people on the confirmation statement. This stock split statement talks of 1:5000 split. Not sure how to read all these documents together?